PHILADELPHIA, May 5, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the relocation of its corporate headquarters from Franklin, MA to Philadelphia, PA.
The new office is located in the heart of Philadelphia's Center City Business District at 8 Penn Center. Echo will continue to maintain and grow its Franklin office as its key operations hub where its engineering and product personnel are located.
"Since Echo Therapeutics' inception, the company has maintained its headquarters in Franklin where we have enjoyed a rewarding history of growth and success," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "The new headquarters responds directly to Echo's growing and evolving business and will accommodate both recent team expansion and additional hires planned for 2011 and beyond."
Echo operates at the following locations:
8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA 19103 (Headquarters)
10 Forge Parkway, Franklin, MA 02038
About Echo TherapeuticsEcho Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. For More Information:Patrick T. Mooney, M.D.
Media: Richard SternChairman and Chief Executive Officer
Stern &Co.(215) 717-4100
(212) 888-0044Connect With Us:- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx<